Autologous stem cell transplantation in immunoglobulin light chain XXXX with @entity11888 .

@entity1 @entity644 @entity548 @entity2783 @entity1112 @entity11888
UNASSIGNED: Acquired @entity11888 and associated @entity548 can be consequences of immunoglobulin light chain @entity2783 . There are limited data on the safety and efficacy of autologous stem cell transplant (ASCT) on @entity11888 . We retrospectively reviewed immunoglobulin light chain @entity2783 @entity1 with factor X levels below 50%, not on chronic anticoagulation who underwent ASCT at the Mayo Clinic, Rochester, Minnesota, USA, between April 1995 and December 2011. Twenty-seven of 358 @entity1 (7.5%) met study criteria. Median pre-ASCT factor X was 36% (range: 2-49%). The most frequent and severe @entity548 complications occurred in @entity1 with factor X levels below 10%. Peri-procedural prophylaxis included activated recombinant factor VII, fresh frozen plasma and platelet transfusions. Steady-state post-ASCT factor X levels were determined in 12 @entity1 . Post-ASCT factor X levels increased in 100% of @entity1 , with median factor X improvement of +32% (range: +8 to +92%). About 46.2% of @entity1 were no longer factor X deficient after ASCT. The degree of improvement in factor X levels was correlated with an improvement in markers of renal involvement by amyloid. Improvement in factor X correlated with an improvement in the degree of total serum protein (  =0.54; P=0.04) and @entity644 (  =-0.54; P=0.04). Our findings support the decision to offer ASCT to factor @entity1112 @entity1 as both appropriate and efficacious.
